Literature DB >> 23089566

Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.

Sara C Meyer1, Alix O'Meara, Andreas S Buser, André Tichelli, Jakob R Passweg, Martin Stern.   

Abstract

In patients referred for allogeneic hematopoietic stem cell transplantation (HSCT), iron overload is frequent and associated with increased morbidity and mortality. Both the evolution of iron overload after transplantation and its correlation with late posttransplantation events are unknown. We studied 290 patients undergoing myeloablative allogeneic HSCT between 2000 and 2009. Serum ferritin, transferrin saturation, transferrin, iron, and soluble transferrin receptor were determined regularly between 1 and 60 months after HSCT, and values were correlated with transplantation outcome. Ferritin levels peaked in the first 3 months posttransplantation and then decreased to normal values at 5 years. Transferrin saturation and iron behaved analogously, whereas transferrin and soluble transferrin receptor increased after an early nadir. Landmark survival analysis showed that hyperferritinemia had a detrimental effect on survival in all periods analyzed (0 to 6 months P < .001; 6 to 12 months P < .001; 1 to 2 years P = .02; 2 to 5 years P = .002). This effect was independent of red blood cell transfusion dependency and graft-versus-host disease. Similar trends were seen for other iron parameters. These data show the natural dynamics of iron parameters in the setting of allogeneic HSCT and provide evidence for a prognostic role of iron overload extending beyond the immediate posttransplantation period. Interventions to reduce excessive body iron might therefore be beneficial both before and after HSCT.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089566     DOI: 10.1016/j.bbmt.2012.10.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  21 in total

1.  Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).

Authors:  Takayoshi Tachibana; Junya Kanda; Shinichiro Machida; Takeshi Saito; Masatsugu Tanaka; Yuho Najima; Satoshi Koyama; Takuya Miyazaki; Eri Yamamoto; Masahiro Takeuchi; Satoshi Morita; Yoshinobu Kanda; Heiwa Kanamori; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2018-01-05       Impact factor: 2.490

2.  Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.

Authors:  Philippe Armand; Haesook T Kim; Johanna M Virtanen; Riitta K Parkkola; Maija A Itälä-Remes; Navneet S Majhail; Linda J Burns; Todd DeFor; Bryan Trottier; Uwe Platzbecker; Joseph H Antin; Martin Wermke
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

3.  Bacterial foodborne infections after hematopoietic cell transplantation.

Authors:  Nicole M Boyle; Sara Podczervinski; Kim Jordan; Zach Stednick; Susan Butler-Wu; Kerry McMillen; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-12       Impact factor: 5.742

4.  Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation.

Authors:  L Chee; M Tacey; B Lim; A Lim; J Szer; D Ritchie
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

Review 5.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

6.  Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.

Authors:  G Visani; B Guiducci; C Giardini; F Loscocco; T Ricciardi; A Isidori
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

7.  Organ siderosis and hemophagocytosis during acute graft-versus-host disease.

Authors:  Axel Nogai; Yu Shi; Daniel Pérez-Hernandez; Steffen Cordes; Jörg Mengwasser; Sarah Mertlitz; Katarina Riesner; Martina Kalupa; Jan-Hendrik Erdmann; Reinhard Ziebig; Gunnar Dittmar; Olaf Penack
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

8.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

9.  Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin.

Authors:  Xiang Li; Feng Xu; Ekapun Karoopongse; A Mario Marcondes; Kayoung Lee; Kris V Kowdley; Carol H Miao; Grant D Trobridge; Jean S Campbell; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-22       Impact factor: 5.742

10.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Authors:  Bryan J Trottier; Linda J Burns; Todd E DeFor; Sarah Cooley; Navneet S Majhail
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.